Waymond D Bray

Array ( [id] => 19151179 [patent_doc_number] => 11976075 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-05-07 [patent_title] => Inhibitors of the MYST family of lysine acetyl transferases [patent_app_type] => utility [patent_app_number] => 18/356923 [patent_app_country] => US [patent_app_date] => 2023-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 101485 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18356923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18725715 [patent_doc_number] => 20230339904 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS [patent_app_type] => utility [patent_app_number] => 18/302787 [patent_app_country] => US [patent_app_date] => 2023-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30241 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18302787 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18786047 [patent_doc_number] => 20230374008 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => BICYCLIC COMPOUNDS [patent_app_type] => utility [patent_app_number] => 18/302554 [patent_app_country] => US [patent_app_date] => 2023-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18020 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18302554 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18692513 [patent_doc_number] => 20230322792 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => CDK9 INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/296930 [patent_app_country] => US [patent_app_date] => 2023-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20395 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18296930 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18673134 [patent_doc_number] => 20230310615 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => OPHTHALMIC COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 18/191957 [patent_app_country] => US [patent_app_date] => 2023-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7886 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 153 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18191957 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18674968 [patent_doc_number] => 20230312488 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => PROCESS FOR THE PREPARATION OF TAUTOMERIC FORMS OF SUNSCREENS [patent_app_type] => utility [patent_app_number] => 18/191112 [patent_app_country] => US [patent_app_date] => 2023-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 783 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18191112 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18657648 [patent_doc_number] => 20230303580 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES [patent_app_type] => utility [patent_app_number] => 18/190224 [patent_app_country] => US [patent_app_date] => 2023-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 101038 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -97 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18190224 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18647693 [patent_doc_number] => 20230293463 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => Treatment of cutaneous neurofibromas with Mirdametinib [patent_app_type] => utility [patent_app_number] => 18/185200 [patent_app_country] => US [patent_app_date] => 2023-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11724 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18185200 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18649333 [patent_doc_number] => 20230295124 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/122323 [patent_app_country] => US [patent_app_date] => 2023-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22152 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -56 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18122323 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18955056 [patent_doc_number] => 20240043383 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => METHOD OF PREPARING INDOLIN-2-ONE COMPOUND AND METHOD OF USING INDOLIN-2-ONE [patent_app_type] => utility [patent_app_number] => 18/178765 [patent_app_country] => US [patent_app_date] => 2023-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1260 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18178765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19241993 [patent_doc_number] => 12012412 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-18 [patent_title] => Solid forms of pyrazolo[3,4-d]pyrimidine compounds [patent_app_type] => utility [patent_app_number] => 18/082622 [patent_app_country] => US [patent_app_date] => 2022-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 21297 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18082622 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18389760 [patent_doc_number] => 20230157978 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => APE/REF1 INHIBITORS FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/990401 [patent_app_country] => US [patent_app_date] => 2022-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8886 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17990401 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18375839 [patent_doc_number] => 20230150920 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-18 [patent_title] => SALTS AND SOLID FORMS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE [patent_app_type] => utility [patent_app_number] => 17/987855 [patent_app_country] => US [patent_app_date] => 2022-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 146159 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17987855 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18345848 [patent_doc_number] => 20230133958 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K [patent_app_type] => utility [patent_app_number] => 17/970443 [patent_app_country] => US [patent_app_date] => 2022-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22309 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17970443 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18320741 [patent_doc_number] => 20230118869 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S DISEASE COMPRISING PHOSPHOLIPASE C ACTIVATOR AS AN ACTIVE INGREDIENT [patent_app_type] => utility [patent_app_number] => 17/965941 [patent_app_country] => US [patent_app_date] => 2022-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9957 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17965941 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18293614 [patent_doc_number] => 20230103300 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-06 [patent_title] => TOPICAL PHARMACEUTICAL COMPOSITION IN GEL FORM COMPRISING AT LEAST AMITRIPTYLINE FOR USE IN THE TREATMENT OF CORONAVIRUS-INDUCED NEUROPATHIC PAIN [patent_app_type] => utility [patent_app_number] => 17/936813 [patent_app_country] => US [patent_app_date] => 2022-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6799 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17936813 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18269164 [patent_doc_number] => 20230090406 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => 6-MEMBERED HETEROARYL-CONTAINING AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/822445 [patent_app_country] => US [patent_app_date] => 2022-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 84735 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 747 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17822445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18064431 [patent_doc_number] => 20220395518 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-15 [patent_title] => Method And Kit For Analysis Of Drug Resistance Of Tumor Cells [patent_app_type] => utility [patent_app_number] => 17/837417 [patent_app_country] => US [patent_app_date] => 2022-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2922 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17837417 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17241852 [patent_doc_number] => 20210361595 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => EPINEPHRINE SPRAY FORMULATIONS [patent_app_type] => utility [patent_app_number] => 17/313933 [patent_app_country] => US [patent_app_date] => 2021-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 85046 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17313933 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17034967 [patent_doc_number] => 20210251925 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => TRANS-4-HYDROXYCYCLOHEXYL PHENYL AMIDE MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/245388 [patent_app_country] => US [patent_app_date] => 2021-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20974 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17245388 [rel_patent_id] =>[rel_patent_doc_number] =>)